A former Bristol-Myers Squibb vice president has joined Hampton’s Celldex Therapeutics Inc.
Dr. Margo Heath-Chiozzi will be the senior vice president of regulatory affairs for the drug company.
She has more than 25 years of experience in senior leadership roles in regulatory sciences, pharmacogenetics and product development within the pharmaceutical industry and as a practicing physician and clinical researcher.
“Dr. Heath-Chiozzi’s strong track record of drug approvals and her exceptional understanding of the regulatory environment position her well to lead our global regulatory strategy,” said Anthony Marucci, Celidex’s co-founder, CEO and president. “She is sincerely passionate about drug development and making a difference in the lives of patients, and we look forward to working with her as we execute across our deep pipeline of drug candidates.”
Heath-Chiozzi joined Bristol-Myers Squibb in 2003, and, while there, supported the global launches of several successful therapies in the areas of oncology, inflammation and infectious disease, including Yervoy, Sunvepra and Reyataz.
“I’m looking forward to working with the Celldex team to develop commercial strategies across its deep pipeline, especially as topline results from the METRIC study of glembatumumab vedotin in patients with triple-negative breast cancer are anticipated within the coming months,” she said. “It’s an exciting time for the organization, and I’m thrilled to be a member of the team.”
From 1995 to 2003, Heath-Chiozzi served in roles of increasing responsibility at Abbott Laboratories. Before that, she was appointed to the University of Hawaii John A. Burns School of Medicine, where she served as assistant professor, and was concurrently director of the HIV Research Clinical at the Queen’s Medical Center as well as director of the Women’s Immunology Clinical at the Kapiolani Medical Center for Women and Children, in Honolulu.
